• Investor Home
  • David C. Pacitti Joins Apollo Endosurgery Board of Directors

David C. Pacitti Joins Apollo Endosurgery Board of Directors

Thursday, November 16, 2017 3:59 pm CST

Public Company Information:

NASDAQ:
APEN
"David is a highly accomplished leader in the medical device field, with deep and relevant commercial leadership gained from experience with respected and leading companies in their fields"

AUSTIN, Texas--(BUSINESS WIRE)--The Board of Directors of Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), today announced the appointment of David C. Pacitti as an independent director of Apollo. He will commence service on December 8, 2017.

Mr. Pacitti’s appointment expands the Board of Directors to nine, with the exception of our Chief Executive Officer, all of whom are independent within the meaning of the applicable NASDAQ listing standards. Mr. Pacitti will be a member of the Compensation Committee of the Board.

“David is a highly accomplished leader in the medical device field, with deep and relevant commercial leadership gained from experience with respected and leading companies in their fields,” said Rich Meelia, Chairman of the Board of Directors of Apollo. “We are very confident that David will add great value to our Board and that Apollo will benefit from his insight, judgment and counsel.”

Mr. Pacitti is currently the President and CEO of Siemens Medical Solutions, North America and Head of North America-Siemens Healthineers where he has responsibility for Siemen’s multi-billion dollar commercial operation in the United States. Prior to his role at Siemens, Mr. Pacitti was with Abbott Vascular in a variety of commercial leadership roles. Mr. Pacitti is a graduate of Villanova University and serves on the board of directors of the Advanced Medical Technology Association (AdvaMed).

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on the design, development and commercialization of innovative medical devices that can be used for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. Apollo’s device based therapies are an alternative to invasive surgical procedures. Apollo's products are offered in over 80 countries today.

Apollo’s common stock is traded on NASDAQ Global Market under the symbol "APEN." For more information regarding Apollo Endosurgery, go to: apolloendo.com.

Contact:

Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
Chief Financial Officer
investor-relations@apolloendo.com
or
The Ruth Group
Lee Roth or Zack Kubow, 646-536-7000
apolloendo@theruthgroup.com

Business Wire InvestorHQ℠